James J. O'Brien
Analyst · Credit Suisse
Thanks, Kevin. Year-over-year, 2 of our 3 commercial units posted solid results with both top line and earnings growth. Sequentially, we saw better-than-expected performance from across all of our businesses. Within ASI, we saw top line improvement from the December quarter, with sales growing 11% and EBITDA margin returning to the 20% level. With our global restructuring in full swing, we expect ASI to begin reaping the benefits of cost savings in the third quarter of approximately $5 million. At the same time, we also expect continued volume growth and pricing improvement resulting from the strategic actions that Luis and his team are taking. Within Performance Materials, adhesives and composites posted another solid quarter, and elastomers performance improved considerably over the prior year. As indicated in the release yesterday, we are restarting the process to sell the elastomers business. We also announced in early April an agreement to sell our ASK Chemicals joint venture. We expect our half of the cash proceeds to be roughly $100 million. Valvoline had a record second quarter for operating income, led by a strong performance in Valvoline Instant Oil Change. International volumes grew 9%, continuing our pattern of strong growth over the past several quarters. We also saw another quarter of improved mix with sales from premium products increasing to over 37% of total sales. When considering Ashland's overall performance, I am encouraged by the strength I'm seeing in our business. I am optimistic about the balance of the year, as we build on this momentum and begin to see the benefits from our global restructuring program. We still have work to do on driving growth and removing costs from the business, but we are moving in the right direction. Please turn to Slide 6. I'd like to take a moment and highlight the investment thesis for Ashland. We have launched and executed a number of value-creating initiatives over the past several quarters, and I don't believe they are fully appreciated by the investment community. The first is the cost savings associated with the global restructuring program. We have identified $200 million in cost savings. On a run rate basis, we expect to achieve more than half by the end of this fiscal year. As you just heard from Kevin, we are committed to not only achieving the target, but also to holding on to these savings. The second initiative is the restructuring of our businesses to be more competitive, agile and efficient. ASI will be a much more streamlined business with increased regional focus ultimately getting us closer to our customers. Fewer layers in the organization will improve accountability and the speed of decision-making, particularly at the regional level. In addition, the realignment of I&S into Performance Materials and adhesives into ASI, will provide a better look at the inherent stability of ASI's core product lines. Based on the proactive changes we are taking, we expect ASI EBITDA margins to return to the targeted 25% to 27% range by the end of fiscal 2015. 2/3 of Ashland's margin expansion will come from initiatives, well within our control like our global restructuring program. Lastly, we expect the $1.4 billion in proceeds for the Water Technologies transition, as well as the cash flow we generated in 2014 and the cash currently on the books. We will have more than $25 per share in cash to use toward value-creating projects. As indicated before, we have a $1.35 billion share buyback authorization program that we intend to use. Additionally, we will continue to invest in high-return capital projects and to evaluate bolt-on acquisitions and targeted debt reduction opportunities. Next slide. Going forward, we see significant opportunities for continued share price expansion with our 4 primary levers. First is growth. Over the long term, we expect Ashland's revenues to grow an excess of global GDP, with peak growth at roughly 1.5x global GDP. This growth will be supported by a variety of macroeconomic tailwinds. These include aging demographics, a growing global middle class, improved construction markets and a growing global car count. We intend to leverage Ashland's innovative technology platforms within pharmaceutical excipients, personal care products, deposit resins and high-performance lubricants to capitalize on these opportunities. As we begin to realize the full cost savings benefit from our global restructuring in fiscal 2015, we expect earnings to grow in the high-single-digit range. Second is margins. We believe the proactive steps we are taking to become more competitive should increase Ashland's EBITDA margin to approximately 20%. With a more efficient operating model in place, we expect to generate higher volumes and command better pricing that should lead to further margin improvement. This improved margin profile should better reflect our specialty chemical focus. Third is free cash flow. Over the past several years, we have increased our free cash flow generation considerably. We expect to generate roughly $275 million to $300 million this fiscal year. We'll use this cash to optimize our balance sheet, invest in high-growth projects, pursue attractive bolt-on acquisitions and return capital to shareholders. Fourth is value. Despite the actions we've taken over the past several years to transform Ashland into a more stable, higher-margin company, we continue to trade at a discount to the broader chemical group. Furthermore, if you compare us to the higher-value specialty chemical names, Ashland trades at a significant discount versus its earnings and EBITDA. We continue to believe the market does not fully appreciate the value of the portfolio of assets and we view Ashland's stock as a good investment opportunity. Beginning in the June quarter, we intend to purchase shares under our previously authorized $1.35 billion repurchase program. Before we open up for your questions, I want to share some thoughts on my decision to retire at the end of December. It was not an easy decision, but I believe the time is right. By the end of this year, Ashland's global redesign will be largely finished, and the sale of Ashland Water will be complete. Although Ashland will be a smaller company, we will be more focused on our core specialty chemicals business and should be better positioned for sustained sales and earnings growth. We'll be more agile and more accountable. We'll be closer to our customers. We'll be able to make faster decisions. We are not quite there yet, but are moving in the right direction. The timing is also right on a personal basis. Our transformation as a global specialty chemical company tops the list. Back in 2002, Ashland was an American conglomerate doing business in a variety of industries, ranging from oil refining and marketing to highway construction and distribution. Specialty chemicals made up only 16% of Ashland's annual sales. More than a decade and 2 dozen deals later, Ashland is truly a global chemical company with a clear focus on specialty chemicals. Our shareholders have reaped the benefits of that transformation, as Ashland's stock has climb from around $26 per share in October 2002 to $97 today. I am incredibly proud of what we have all accomplished, and I feel lucky to have played a role in Ashland's success. At the same time, I am excited about the opportunities that lie ahead, both for the company and for me personally. My announcement at this particular point in time gives the Board of Directors an appropriate amount of time to conduct a thorough search as part of an orderly succession plan. Let me be clear. Ashland's strategic focus won't change. Specialty chemicals is a cornerstone of this company and the foundation on which our future will be built. I am confident the board will appoint a new CEO with the vision and experience necessary to lead Ashland into the upper echelon of specialty chemical companies, with EBITDA margins to match. Until then, we have a lot of work to do. I intend to be fully engaged over the next 8 months to make sure we finish what we have started. Now I'll hand it over to Jason to begin Q&A.